SM-86(Lipid 5)
DC31024
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | 2089251-49-8 |
| Chemical Name | Moderna Lipid 26（Lipid M） |
| Synonyms | Heptadecan-9-yl 8-((2-hydroxyethyl)(4-(nonyloxy)-4-oxobutyl)amino)octanoate,Moderna-Lipid-26，Moderna Lipid-26 |
| SMILES | O(C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])O[H])C([H])([H])C([H])([H])C([H])([H])C(=O)OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)C([H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] |
| Formula | C40H79NO5 |
| M.Wt | 654.0590 |
| Purity | >95% by ELSD-HPLC |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Hassett KJ, Benenato KE, Jacquinet E, et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol Ther Nucleic Acids. 2019;15:1-11. US20170210697A1. Compounds and compositions for intracellular delivery of therapeutic agents. ModernaTx, Inc.; published 2017-07-27. |
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| Lipid M / Moderna Lipid 26 | 50 | Ionizable lipid |
| DSPC | 10 | Helper phospholipid |
| Cholesterol | 38.5 | Sterol |
| PEG lipid | 1.5 | PEG lipid |
| Reported total | 100 | Source values retained |
Formulation calculator unavailable. Calculator disabled: the article gives the four mol% values, but the PEG-lipid chemical identity and molecular weight are not disclosed. Do not substitute a commercial PEG lipid or infer a component mass. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reported6.75Lipid M structure panelMain article Fig. 3A, journal p. 4
Literature-reportedH10N8 ELISA and HAI titers for Lipid M were not statistically different from MC3 in the reported group-level comparisons.5 mg modified H10N8 mRNA IM per dose; n=3 cynomolgus monkeys/group; days 0, 21, 42Main article Fig. 4A-B and caption, journal pp. 5-6
Literature-reportedLipid M showed more expression over time than MC3 in the study's comparison (p=0.05).IM modified mRNA encoding antibody heavy/light chainsMain article p. 4 and Fig. 4C caption, journal pp. 4-5
Literature-reportedAverage scores for Lipid M at 0.01 mg were muscle fiber necrosis 2.0, muscle mixed-cell inflammation 2.0, muscle degenerate neutrophils 1.3, skin mixed-cell inflammation 1.7, and skin degenerate neutrophils 0; at 0.1 mg: 1.7, 2.7, 2.0, 2.0, and 0, respectively.Zika prM-E mRNA IM; n=3/group; 48 h; 0–4 pathology scaleMain article Table 1, journal p. 6
Literature-reportedLead-lipid levels declined faster than MC3 in muscle, spleen, and liver after IM administration; Lipid M is one of the five lead lipids shown in Fig. 3B-D.Luciferase mRNA LNPs in CD-1 mice; n=3/time point; up to 48 hMain article Fig. 3B-D and journal p. 3
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetHassett KJ, Benenato KE, Jacquinet E, et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol Ther Nucleic Acids. 2019;15:1-11.
Formulation and performance source locations are listed with the evidence items above.
Formulation and performance source locations are listed with the evidence items above.
PMC full article · Europe PMC full text XML · Europe PMC supplementary files · Patent US20170210697A1 · DOI